Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
about
Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis CIn-cell protease assay systems based on trans-localizing molecular beacon proteins using HCV protease as a model systemCost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.Integration of PKPD relationships into benefit-risk analysisSynthesis and facile end-group quantification of functionalized PEG azidesInterferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis.Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.Economic assessment of eltrombopag in the treatment of thrombocytopenia.Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General HospitalThe cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.[Therapy of vasculitides and vasculopathies]Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review.Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis CSofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisEvidence-based clinical guidelines for immigrants and refugees.Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis CPredictive factors associated with hepatitis C antiviral therapy response.Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patientsClinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Management of leukocytoclastic vasculitis.Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis.Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancerA systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysisThe Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian StudyCritical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.Treating hepatitis C in the prison population is cost-saving.Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas.Are adverse effects incorporated in economic models? A survey of current practice.Current drug discovery strategies for treatment of hepatitis C virus infection.Hepatitis C virus infection and mixed cryoglobulinemiaPrevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence.Latent cytokines for targeted therapy of inflammatory disorders.Orofacial adverse effects of biological agents.Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
P2860
Q24246836-FFF4745F-C4B1-4A05-AC31-434B517F6F6EQ28488653-688C4B4B-1F4A-4372-A902-EE9400188DC9Q30422586-7A63C83E-1792-43CD-9CD9-D3C577CC3628Q30671571-E3418845-5FFD-42D1-BFA6-D48BB8DF9B95Q31142167-5E4DE87B-0E54-4352-9886-2F99EDF6A121Q31155562-AD0B9ADB-52BF-4622-AF7B-47F681CEA31EQ33282460-28F4280C-E806-4F68-9D46-556DD5958553Q33424436-36F4CEED-CDFF-45FE-AE95-0FCA6FCB6662Q33810973-3F640D49-CC09-44B8-A9A3-F2B45F3C02C7Q33834958-CA3375EC-503A-414F-B388-7D0BCB93A7F9Q34596838-23D3E523-72D6-476D-A1AF-292BE9756194Q34616264-91650B77-CE4C-44B7-AE32-872D775842CFQ34954320-E3006743-3C06-4FBE-A5DB-4A743604F462Q35031753-2EE6E994-ADA6-40CB-9DE5-1F8EFD44C10BQ35037688-4714235C-F97F-443E-8D23-35FA7B01A09DQ35201293-59D1BA1E-9812-4F95-B4D1-8D48393DDE70Q35640461-B3BEF74F-CE64-474B-A9D6-8DF74E5967E2Q35790397-3FA5E76B-EB18-47D9-AFB0-95B643391DDBQ35925546-9FBD7343-8A67-48F7-9352-99410E40A3ABQ36057034-E3A7A436-07FA-47CB-921D-9EBE095DBF5CQ36297037-4A12FDEB-EFFC-4167-B4F3-EFB6C5C8E333Q36301391-51C7A250-F67E-4B1C-BB14-DC27C141B759Q36530402-1AC229F8-A533-46E5-B635-04A35B792C93Q36607811-70FCEEDB-62A6-4173-8039-2AF812FF8EABQ36698872-B8851263-F43C-4B2F-9DD0-CC9B444310D4Q36715901-88B64E27-F4B8-46D8-972F-79D0CF684611Q37035896-EC5C7C3D-A176-4987-851B-F3DC6B5F6117Q37067776-4FDB6CE9-D690-44F8-A5EC-F6242A5EA96CQ37142229-941CD106-E460-465E-ABCA-FCE2AE12394BQ37222388-94350B2D-C4DE-40A3-8CE8-8973F6F9E8F9Q37299503-0E9E54C1-9EB8-4EF0-8926-9323EF43E731Q37363382-FEDAAE83-42D1-460F-987E-44673C42C545Q37466205-800D57F9-3612-457B-B0D9-E8901809E6C2Q37768240-8842DADC-0B9D-493B-9071-1E6FC1B968D6Q37884087-F1AA02F6-1895-4437-9010-848304E37CC9Q38030533-4BD315B4-46E0-4998-9C68-E171207CB848Q38086360-DF1DC7B8-7077-4F9B-8F96-09E28FE4F3CFQ38167818-EDD1C3F1-6400-4C2C-98BC-712003D4E68CQ38213692-AF111D3F-211C-4C55-8002-60EA02BA1403Q38544516-C18BBA07-CF48-4493-87B7-709C13AA5492
P2860
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@ast
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@en
type
label
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@ast
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@en
prefLabel
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@ast
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@en
P2093
P356
P1476
Pegylated interferon alpha-2a ...... eview and economic evaluation.
@en
P2093
P304
iii-iv, 1-125
P356
10.3310/HTA8390
P577
2004-10-01T00:00:00Z